Skip to main content
Belgian Biosafety Server
Search form
Search
EN
FR
NL
Toggle navigation
Home
Notification procedures
Contained use GMOs/pathogens
Brussels-Capital
Flanders
Wallonia
Supporting tools
Emergency plans GMMs
Some figures
Clinical Trials GMOs
Supporting tools
Database
Some figures
Environmental release GMOs for R&D
Supporting tools
Database
Some figures
Commercialisation medicinal GMOs
Supporting tools
Some figures
Authorisations GMO-human
Authorisations GMO-veterinary
Commercialisation GMOs environment or food/feed
Supporting tools
Some figures
Dossier C/BE/96/01
Regulatory framework
EU framework
Contained use GMMs
Deliberate release GMOs
Decisions releases GMOs
GM Food/Feed
Medicinal GMOs
Worker's protection
Other regulations
Belgian framework
Cooperation agreement
Historical steps
Biosafety Council
SBB
Contained use GMOs/pathogens
Certification and exemptions
Historical perspective
Deliberate release GMOs
Historical background
Scientific assessment
NRL-GMO
Worker's protection
Thematic Areas
Assessment bio-risks
Biosecurity
LAI
Genome editing
Polio eradication
Synthetic biology
Transport
Historical Background
Biological risk classification
Recombinant DNA
GMO - From lab to field
OECD activities
EU GMO Directives
EU GMO definition
FAQ
Events
Upcoming Events
Past Events
Our events
MEACB 2017
Biosafety training (HE2B)
About the SBB
Tasks and activities
Risk assessment
Scientific support
International
Networking activities of the SBB
Research
Communication
Publications
Contact Us
* NEW (25-06-2025) *
cellpoint b.v.
schering n.v./s.a.
Search the database for deliberate release of GM medicinal products
Search the database for deliberate release of GM medicinal products
Displaying 1 - 7 of 7
Fulltext search
Search
Reset
EU record number
Title
Company / Sponsor
Treated organism
Genetic modification
Only notified under the "contained use" procedure. Dossier submitted on
25/07/2022
.
A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (SLL)
CellPoint B.V.
Humans
CD19 CAR
Only notified under the "contained use" procedure. Dossier submitted on
07/06/2022
.
A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured anti-BCMA CAR T cells (BCMACP03) in subjects with relapsed/refractory Multiple Myeloma (r/r MM) (Papilio-1)
CellPoint B.V.
Humans
BCMA CAR
CP0201-NHL
A Phase I/II, multicenter study, evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodglin lymphoma
CellPoint B.V.
Humans
CD19-CAR
Only notified under the "contained use" procedure. Dossier submitted on
11/07/2002
.
A European and Canadian multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Ad5FGF-4 in patients with stable angina
Schering N.V./S.A.
Humans
human FGF-4
B/BE/98/B6
Clinical research program : Gene-therapy by the Use of a Recombinant Adenovirus in the Treatment of p53 Deficient Cancers
Schering Plough NV/SA
Humans
wild-type p53 tumor suppressor gene
Only notified under the "contained use" procedure. Dossier submitted on
18/08/1997
.
A phase II gene therapy study in patients with non-small cell lung cancer using SCH58500 (rAd/p53) in combination with chemotherapy for multiple cycles
Schering Plough NV/SA
Humans
Wild-type p53
Only notified under the "contained use" procedure. Dossier submitted on
21/10/1996
.
A phase I study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck using SCH 58500 (rAd/p53) administered by single intratumoral injection
Schering Plough NV/SA
Humans
Wild-type p53
Showing 1 to 7 of 7 entries